The peer-reviewed study, entitled “US Cannabis Laws Projected To Cost Generic And Brand Pharmaceutical Firms Billions”, analyzed how publicly traded pharmaceutical firms fared after adult-use or medical marijuana laws were enacted by states. According to Ziemowit Bednarek, California Polytechnic State University’s Finance Department, together with Sarah Stith, pharmaceutical stocks were worth 1.5-2% lower in only 10 days following cannabis legalization.
The Trump administration is preparing to move cannabis from Schedule I to Schedule III of…
Based on the ruling, products that are legal federally as well as at the state…
The drug’s history of healing and experimentation stretches from ancient China to American counterculture —…
The new partnership will spotlight the stories of people still behind bars for cannabis, support…
Colombia is moving forward with a controversial plan to euthanize dozens of invasive hippos descended…
Imported hashish sustained mountain economies for centuries—until modern legalization and market economics erased it almost…